Naprux en es it fr

Naprux Brand names, Naprux Analogs

Naprux Brand Names Mixture

  • No information avaliable

Naprux Chemical_Formula


Naprux RX_link

No information avaliable

Naprux fda sheet

Naprux FDA

Naprux msds (material safety sheet)

Naprux MSDS

Naprux Synthesis Reference

No information avaliable

Naprux Molecular Weight

158.17 g/mol

Naprux Melting Point

> 160 oC

Naprux H2O Solubility

No information avaliable

Naprux State


Naprux LogP

No information avaliable

Naprux Dosage Forms

Capsule; Drops; Liquid; Powder for solution; Solution; Tablet

Naprux Indication

Used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.

Naprux Pharmacology

Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

Naprux Absorption

40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.

Naprux side effects and Toxicity

Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).

Naprux Patient Information

No information avaliable

Naprux Organisms Affected

Humans and other mammals